Marina Pasca Di Magliano
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (42)
Year:
2026
Pancreatic ductal adenocarcinoma (PDAC) is characterized by profound metabolic rewiring and a strongly immunosuppressive tumor microenvironment, both of which contribute to poor therapeutic responses. Immunogenic cell death (ICD) represents a potential strategy to overcome immune suppression by coupling tumor cell death to anti-tumor immune activation. Here, we investigated whether targeting amino acid metabolism in PDAC can induce ICD and promote tumor immunity. Through a focused metabolic screen in a panel of syngeneic mouse cancer cell lines, we identified cysteine restriction as a robust inducer of multiple damage-associated molecular patterns (DAMPs) in vitro, hallmark features of ICD. In addition to driving DAMPs, cystine-deprived tumor cells also promoted dendritic cell phagocytosis, maturation, and proinflammatory cytokine production in vitro. Because cysteine deprivation is a known trigger of ferroptosis, we further demonstrated that pharmacologic inhibition of glutathione peroxidase 4 (GPX4) similarly elicited ICD-associated features, which were reversible by the ferroptosis inhibitor Ferrostatin-1. To define additional immune-modulatory signals associated with ferroptosis, we performed metabolomic and lipidomic profiling of cells undergoing, but not yet committed to, ferroptotic death. These analyses revealed selective release of immunosuppressive metabolites and oxidized phospholipids. Consistent with this, conditioned media from ferroptotic cells impaired CD8⁺ T cell proliferation and cytotoxicity in vitro. Thus, together our results indicated that the induction of ferroptotic immunogenic cell death led to the release of both pro- and anti-inflammatory signals. Subsequent analysis in vivo revealed that ferroptotic tumor cells predominantly contributed to a tumor-protective environment. In particular, tumors inoculated with ferroptotic cells were enriched with immunosuppressive myeloid cells and exhibited reduced populations of tumor-infiltrating CD8+ T cells. Further investigation using immune compromised mice suggested that ferroptotic cells may suppress both adaptive and innate immune responses. Collectively, these results underscore the complex and highly context-dependent effects of ferroptosis on tumor immunity, highlighting the critical importance of in vivo models to determine true immunogenic potential within the tumor microenvironment.
Year:
2026
Supplementary Figure 3 shows gating strategies used for flow analysis of CD4 cells from orthotopic tumors as well as serum and tissue IL22 measured by ELISA. IHC and multiplex IHC analysis of TCDD treated tumors in the absence of T regulatory cells is shown.
Year:
2026
Although smoking is a risk factor for pancreatic adenocarcinoma (PDAC), the underlying mechanisms promoting tumorigenesis and progression are unknown. In this study, we show that aryl hydrocarbon receptor (AHR) ligands found in cigarette smoke, like the carcinogen 2,3,7,8-tetrachlorodibenzo- p -dioxin, promote pancreatic dysplasia and PDAC progression in a mouse model of this disease. This effect is mediated by AHR activation in CD4 + T cells, leading to their polarization to IL22 -producing TH22 cells and regulatory T cell accumulation, ultimately driving a blunted CD8 + T-cell effector response. Analysis of human pancreata from organ donors revealed that smokers have increased AHR activation relative to nonsmokers. Similarly, PDAC tumors from patients with a history of cigarette smoking presented with increased regulatory T-cell accumulation compared with nonsmokers. These findings support a model whereby AHR ligands (AHRL) in cigarette smoke promote tumorigenesis and progression of PDAC through dysregulation of immune responses. Significance: Our study investigates the mechanistic link between AHRL and pancreatic cancer. We determined that AHRLs polarize naïve T cells, resulting in increased production of IL22 and immunosuppression. Our findings identify a novel signaling axis linking environmental chemicals to pancreatic tumorigenesis via the immune system. See related commentary by Zhao and Hill, p. 13
Year:
2026
Supplementary Figure 1 provides additional details of orthotopic tumors treated with TCDD including histology, gross pictures and dose escalation. Data on additional cell lines including in vitro growth kinetics is provided.
Year:
2026
Pancreatic cancer is associated with a high rate of metastasis and poor prognosis. The formation of a premetastatic niche (PMN) facilitates cancer cell spread and contributes to cancer mortality. Using murine pancreatic cancer models based on expression of oncogenic KRAS in the pancreas epithelium, we discovered that remodeling of the lung microenvironment occurred in mice bearing pancreatic precursor lesions prior to cancer formation. This early-lesion PMN resembled the PMN in cancer-bearing mice, and both feature characteristics of overt metastasis, such as transcriptional reprogramming, activation of fibroblast STAT3 signaling, and infiltration of immunosuppressive arginase 1–positive macrophages. Both patients with pancreatic cancer and mouse models demonstrated elevated serum IL6. Inactivating oncogenic KRAS reduced serum IL6 and reverted fibroblast STAT3 phosphorylation in mouse lungs; loss of lung fibroblast STAT3 phosphorylation was similarly observed when mice were treated with the pan-RAS inhibitor RMC-7977. Whereas arginase 1–positive macrophage infiltration was dispensable for fibroblast STAT3 activation, IL6 blockade inhibited lung fibroblast STAT3 activation. Functionally, fibroblast STAT3 activation was necessary for lung metastasis establishment and growth. Interestingly, activation of STAT3 in the PMN was present in the lungs but not in the liver, in which fibroblast reprogramming occurred only in overt metastasis, pointing to organ-specific PMN formation. In human metastasis samples, phosphorylated STAT3 in fibroblasts was similarly more abundant in the lungs than liver. Together, these data point to organ-specific mechanisms driving formation of the PMN and indicate that reprogramming of the microenvironment prior to metastasis might support early dissemination of pancreatic cancer. Significance: Pancreatic oncogenic KRAS drives premetastatic niche formation in the lungs, but not liver, through fibroblast STAT3 activation to promote metastasis, indicating a lung-specific vulnerability for treating pancreatic cancer metastasis. See related commentary by Mucciolo and Biffi, p. 7
Year:
2026
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the United States. This is due in part to the limited availability of effective treatment options for patients, highlighting a significant need for new targets and approaches. Deregulated metabolism is a hallmark feature of PDA that has gained attention as a promising inroad for therapy. The aspartate transaminases ( g lutamate o xaloacetate transaminases, cytosolic GOT1 and mitochondrial GOT2) have several important metabolic functions, including maintaining energy and redox balance and generating aspartate, an essential building block in protein and nucleotide biosynthesis. Previous studies of GOT proteins in preclinical tumor transplant models have yielded conflicting results regarding the requirement of GOT1 and GOT2 for PDA tumor growth. To assess the role of GOT proteins in tumor development and tumor maintenance, we generated conditional knockout mice for Got1 and Got2 and crossed these into pancreas-specific models. Whereas loss of either Got does not impact pancreas development, double Got1 and Got2 knockout results in markedly reduced pancreas size and cellularity without overtly impacting endocrine or exocrine function. In genetically engineered cancer models, single Got loss does not impact lesion formation, tumor size, animal survival, or the composition of the tumor microenvironment. Identical results were also observed in orthotopic allograft mouse models. Together, these findings add to a growing body of work illustrating the adaptability of metabolism in cancer. They also emphasize the importance of model selection, the use of multiple independent models, and the in vivo context when studying the role of metabolic programs in cancer.
Year:
2025
Supplemental Table 1: Demographics and clinical data for donor Gife of Life Samples Supplemental Table 2: Putative Ligand-Receptor pairs comparing all cell types from single cell sequencing of tumor samples compared to healthy samples. Supplemental Table 3: Differential gene expression using linear mixed model analysis of cell types from spatial transcriptomic ROIs. Supplemental Table 4: Kras mutational profiling on select donor samples Supplemental Table 5: Antibodies used for multiplex immunofluoresence. Supplemental Table 6: Antibodies and RNAScope probe used for co-IF/ISH.
Year:
2025
Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). How chemotherapy alters the TME, and whether these changes drive chemoresistance, is poorly understood. We examined matched pre- and post-treatment tissue specimens and found near-universal enrichment of axonal guidance genes in cancer-associated fibroblasts (CAFs) after treatment. These CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrence lesions had the highest prevalence of these CAFs versus primary tumors and untreated metastasis. These CAFs showed elevated non-canonical Wnt mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Our findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising target for this disease. Statement of Significance Therapeutic resistance remains a major challenge in pancreatic cancer. Our findings shed light on the changes in the complex tumor microenvironment in response to chemotherapy and identify fibroblasts high in axonal-guidance genes that may drive tumor progression and chemoresistance, thus uncovering a potential avenue for targeting pancreatic cancer.
Year:
2025
Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely described. We report that liver metastases promote disease progression in patients and preclinical models. Patients with liver metastases progress rapidly, regardless of primary tumor type. In multiple murine models, we find that liver metastases potentiate neutrophil migration and activity. Neutrophils licensed by liver metastasis augment metastatic colonization in an IL1-dependent manner. Thus, liver metastasis rewires systemic immunity to promote cancer progression. This work has implications for treatment strategies to address the poor clinical outcomes associated with liver metastasis.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (52)
Todd Prickett
Staff Scientist
National Institutes of Health
Kyoung Eun Lee
Assistant Professor
University of Michigan Medical School
Carole Parent
Professor
University of Michigan
Paul Romesser
Memorial Sloan Kettering Cancer Center
Christina V. Angeles
University of Michigan
Pankaj Singh
Professor and Chair
University of Oklahoma Health Sciences Center
Arul M Chinnaiyan
University of Michigan
Christopher Sonnenday
University of Michigan
Allison R. Schulman
University of Michigan
Pierre A. Coulombe
G. Carl Huber Professor and Chair
University of Michigan
Jorge Machicado
Assistant Professor
University of Michigan
Kyle Cuneo
Associate Professor
Michigan Medicine
Kirsten Remmert
Staff Scientist
National Institutes of Health
Alexander Rossi
Assistant Professor
Yale University
Scott Bresler
Associate Professor
University of Michigan
Yatrik Shah
Professor
University of Michigan
Margaret Cam
Staff Scientist
National Institutes of Health
Vaibhav Sahai
University of Michigan
Benjamin Allen
Associate Professor
University of Michigan
Dipankar Ray
University of Michigan
Jason Knight
Professor
University of Michigan
Jiaqi Shi
Professor
University of Michigan
Adam Courtney
Assistant Professor
University of Michigan Medical School
Rashmi Chugh
-
Filip Bednar
University of Michigan
Ilona Kryczek
University of Michigan
Rodrigo Xavier das Neves
Research Assistant Professor
University of Pittsburgh
Dana Pe'er
Sloan Kettering Institute
James Yang
National Cancer Institute
Andrzej Dlugosz
Associate Director for Basic Science Research
University of Michigan Rogel Cancer Center
Qiang Zhang
Research Assistant Professor
University of Michigan Medical School
weiping Zou
University of Michigan
Craig Galban
Professor
University of Michigan
Fengming Chen
Duke University Medical Center
Peter J. Allen
Duke University
Carolina Larrain
NYU Langone Health
Reed Ayabe
Assistant Professor
University of California Irvine Medical Center
Michael Green
Assistant Professor
University of Michigan
Timothy Frankel
Assistant Professor
University of Michigan Hospital
Daniel Chang
University of Michigan
Yaqing Zhang
Associate Professor
University of Michigan
Rosa Menjivar
University of California, San Francisco
Direna Alonso Curbelo
Group Leader
IRB Barcelona
THEODORE S. LAWRENCE
Chair, Professor
University of Michigan
Jeremy Davis
Professor and Chief, Division of Surgical Oncology
University of Maryland School of Medicine
Deneen M. Wellik
Professor and Chair
University of Wisconsin-Madison
William Burns
Assistant Professor
Johns Hopkins University School of Medicine
Stefanie Galban
-
Costas A. Lyssiotis
University of Michigan
Nina Steele
Assistant Professor
University of Cincinnati
Chanjuan Shi
Professor
Duke University
sivasish sindiri
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.